- Home
- ORKA vs CSTL Comparison
ORKA vs CSTL Comparison
Compare ORKA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- CSTL
- Stock Information
- Founded
- ORKA 2004
- CSTL 2007
- Country
- ORKA United States
- CSTL United States
- Employees
- ORKA N/A
- CSTL N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CSTL Medical Specialities
- Sector
- ORKA Health Care
- CSTL Health Care
- Exchange
- ORKA Nasdaq
- CSTL Nasdaq
- Market Cap
- ORKA 1.0B
- CSTL 848.1M
- IPO Year
- ORKA N/A
- CSTL 2019
- Fundamental
- Price
- ORKA $11.02
- CSTL $25.75
- Analyst Decision
- ORKA Strong Buy
- CSTL Strong Buy
- Analyst Count
- ORKA 7
- CSTL 6
- Target Price
- ORKA $39.67
- CSTL $40.33
- AVG Volume (30 Days)
- ORKA 263.4K
- CSTL 358.8K
- Earning Date
- ORKA 03-04-2025
- CSTL 02-27-2025
- Dividend Yield
- ORKA N/A
- CSTL N/A
- EPS Growth
- ORKA N/A
- CSTL N/A
- EPS
- ORKA N/A
- CSTL 0.21
- Revenue
- ORKA N/A
- CSTL $311,878,000.00
- Revenue This Year
- ORKA N/A
- CSTL $51.99
- Revenue Next Year
- ORKA N/A
- CSTL N/A
- P/E Ratio
- ORKA N/A
- CSTL $122.41
- Revenue Growth
- ORKA N/A
- CSTL 62.43
- 52 Week Low
- ORKA $10.61
- CSTL $16.97
- 52 Week High
- ORKA $53.88
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- CSTL 37.34
- Support Level
- ORKA N/A
- CSTL $26.65
- Resistance Level
- ORKA N/A
- CSTL $28.48
- Average True Range (ATR)
- ORKA 0.00
- CSTL 1.12
- MACD
- ORKA 0.00
- CSTL -0.17
- Stochastic Oscillator
- ORKA 0.00
- CSTL 0.94
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.